Pranita D Tamma1, Katherine E Goodman2, Anthony D Harris3, Tsigereda Tekle4, Ava Roberts4, Abimbola Taiwo4, Patricia J Simner5. 1. Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, ptamma1@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine. 4. Division of Medical Microbiology, Department of Pathology, Johns Hopkins Hospital, and. 5. Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) are associated with considerable mortality. As mechanisms of carbapenem resistance are heterogeneous, it is unclear if mortality differs based on resistance mechanisms. We sought to determine whether CRE resistance mechanism determination is prognostically informative. METHODS: We conducted an observational study comparing 14-day mortality between patients with carbapenemase-producing (CP)-CRE compared with non-CP-CRE bacteremia. Clinical data were collected on all patients. A comprehensive DNA microarray-based assay was performed on all isolates to identify β-lactamase-encoding genes. RESULTS: There were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and 46 (55%) non-CP-CRE. The majority of CP-CRE isolates were bla KPC (92%), followed by bla NDM (5%) and bla OXA-48-type (3%). CP-CRE isolates were more likely to have meropenem minimum inhibitory concentrations (MICs) ≥16 µg/mL, while non-CP-CRE isolates were more likely to have meropenem MICs ≤1 µg/mL (P value < .001). A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE group and 6 (13%) in the non-CP-CRE group. Adjusting for severity of illness on day 1 of bacteremia, underlying medical conditions, and differences in antibiotic treatment administered, the odds of dying within 14 days were more than 4 times greater for CP-CRE compared with non-CP-CRE bacteremic patients (adjusted odds ratio, 4.92; 95% confidence interval, 1.01-24.81). CONCLUSION: Our findings suggest that CP-CRE may be more virulent than non-CP-CRE and are associated with poorer outcomes. This underscores the added importance of delineating underlying resistance mechanisms of CRE to direct antibiotic treatment decisions.
BACKGROUND:Carbapenem-resistant Enterobacteriaceae (CRE) are associated with considerable mortality. As mechanisms of carbapenem resistance are heterogeneous, it is unclear if mortality differs based on resistance mechanisms. We sought to determine whether CRE resistance mechanism determination is prognostically informative. METHODS: We conducted an observational study comparing 14-day mortality between patients with carbapenemase-producing (CP)-CRE compared with non-CP-CRE bacteremia. Clinical data were collected on all patients. A comprehensive DNA microarray-based assay was performed on all isolates to identify β-lactamase-encoding genes. RESULTS: There were 83 unique episodes of monomicrobial CRE bacteremia during the study period: 37 (45%) CP-CRE and 46 (55%) non-CP-CRE. The majority of CP-CRE isolates were bla KPC (92%), followed by bla NDM (5%) and bla OXA-48-type (3%). CP-CRE isolates were more likely to have meropenem minimum inhibitory concentrations (MICs) ≥16 µg/mL, while non-CP-CRE isolates were more likely to have meropenem MICs ≤1 µg/mL (P value < .001). A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE group and 6 (13%) in the non-CP-CRE group. Adjusting for severity of illness on day 1 of bacteremia, underlying medical conditions, and differences in antibiotic treatment administered, the odds of dying within 14 days were more than 4 times greater for CP-CRE compared with non-CP-CRE bacteremic patients (adjusted odds ratio, 4.92; 95% confidence interval, 1.01-24.81). CONCLUSION: Our findings suggest that CP-CRE may be more virulent than non-CP-CRE and are associated with poorer outcomes. This underscores the added importance of delineating underlying resistance mechanisms of CRE to direct antibiotic treatment decisions.
Authors: B Joris; F De Meester; M Galleni; S Masson; J Dusart; J M Frère; J Van Beeumen; K Bush; R Sykes Journal: Biochem J Date: 1986-11-01 Impact factor: 3.857
Authors: Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: Nora Chea; Sandra N Bulens; Thiphasone Kongphet-Tran; Ruth Lynfield; Kristin M Shaw; Paula Snippes Vagnone; Marion A Kainer; Daniel B Muleta; Lucy Wilson; Elisabeth Vaeth; Ghinwa Dumyati; Cathleen Concannon; Erin C Phipps; Karissa Culbreath; Sarah J Janelle; Wendy M Bamberg; Alice Y Guh; Brandi Limbago; Alexander J Kallen Journal: Emerg Infect Dis Date: 2015-09 Impact factor: 6.883
Authors: Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas Journal: Emerg Infect Dis Date: 2014-07 Impact factor: 6.883
Authors: Patricia J Simner; Belita N A Opene; Krizia K Chambers; Matthew E Naumann; Karen C Carroll; Pranita D Tamma Journal: J Clin Microbiol Date: 2017-07-12 Impact factor: 5.948
Authors: Pranita D Tamma; Belita N A Opene; Andrew Gluck; Krizia K Chambers; Karen C Carroll; Patricia J Simner Journal: J Clin Microbiol Date: 2017-01-11 Impact factor: 5.948
Authors: Alexander Lawandi; Gleice C Leite; Matthew P Cheng; Brigitte Lefebvre; Jean Longtin; Todd C Lee Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191